CIA
MDGL icon

Capital Impact Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Capital Impact Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,726
Closed -$995K – 83
2024
Q1 		$995K Sell
3,726
-1,266
-25% -$298K 1.29% 26
2023
Q4 		$1.16M Buy
4,992
+2,853
+133% +$499K 1.52% 15
2023
Q3 		$312K Hold
2,139
– – 0.52% 78
2023
Q2 		$494K Sell
2,139
-753
-26% -$204K 0.54% 87
2023
Q1 		$701K Buy
2,892
+438
+18% +$119K 0.86% 31
2022
Q4 		$712K Sell
2,454
-5,708
-70% -$558K 0.7% 43
2022
Q3 		$570K Hold
8,162
– – 0.57% 61
2022
Q2 		$584K Sell
8,162
-4,394
-35% -$323K 0.54% 70
2022
Q1 		$1.23M Sell
12,556
-5,693
-31% -$480K 0.9% 15
2021
Q4 		$1.55M Buy
18,249
+6,474
+55% +$532K 1.07% 34
2021
Q3 		$940K Hold
11,775
– – 0.37% 103
2021
Q2 		$1.15M Sell
11,775
-21,273
-64% -$2.52M 0.37% 99
2021
Q1 		$3.87M Buy
33,048
+8,697
+36% +$1.01M 1.35% 25
2020
Q4 		$2.71M Buy
+24,351
New +$2.98M 0.66% 65
2020
Q3 		– Sell
-24,351
Closed -$2.76M – 122
2020
Q2 		$2.76M Hold
24,351
– – 0.92% 39
2020
Q1 		$1.63M Buy
24,351
+996
+4% +$83K 0.68% 68
2019
Q4 		$2.13M Buy
23,355
+2,762
+13% +$268K 0.75% 68
2019
Q3 		$1.75M Buy
20,593
+2,445
+13% +$229K 0.67% 94
2019
Q2 		$1.82M Buy
18,148
+4,489
+33% +$481K 0.67% 74
2019
Q1 		$1.43M Hold
13,659
– – 0.63% 90
2018
Q4 		$1.43M Buy
13,659
+6,458
+90% +$999K 0.61% 93
2018
Q3 		$1.53M Buy
7,201
+596
+9% +$150K 0.52% 103
2018
Q2 		$1.84M Sell
6,605
-4,590
-41% -$806K 0.68% 62
2018
Q1 		$1.31M Buy
+11,195
New +$1.38M 0.54% 101
2015
Q1 		– Sell
-1,080
Closed -$100K – 287
2014
Q4 		$100K Buy
1,080
+1,079
+107,900% +$112K 0.05% 205
2014
Q3 		$114 Sell
1
-1,079
-100% -$150K ﹤0.01% 203
2014
Q2 		$155K Buy
+1,080
New +$158K 0.12% 187

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Impact Advisors's MDGL Position: Q2 2024 in Review

Capital Impact Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2024, closing a stake of 3,726 shares — an estimated $995K sold.

Capital Impact Advisors first reported a position in MDGL in Q2 2014 and held it in 27 quarters. The position peaked at $3.87M in Q1 2021. 257 funds tracked by Wall St. Rank hold MDGL as of Q2 2024.

  • Capital Impact Advisors reported no remaining Madrigal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 3,726 Madrigal Pharmaceuticals shares in Q2 2024, an estimated $995K.
  • Capital Impact Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2014 and held it in 27 quarters.
  • Capital Impact Advisors's Madrigal Pharmaceuticals position peaked at $3.87M in Q1 2021.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2024.

Based on Capital Impact Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.